Literature DB >> 17470653

Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients.

Dwight R Stickney1, Zoja Noveljic, Armando Garsd, Daniel A Destiche, James M Frincke.   

Abstract

Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone. The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42.2% (P < 0.05) and the cumulative incidence of opportunistic infections (P < 0.05). These results warrant further clinical investigation of HE2000.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17470653      PMCID： PMC1913278          DOI： 10.1128/AAC.01446-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  The nature of the principal type 1 interferon-producing cells in human blood.

Authors:  F P Siegal; N Kadowaki; M Shodell; P A Fitzgerald-Bocarsly; K Shah; S Ho; S Antonenko; Y J Liu
Journal:  Science       Date:  1999-06-11       Impact factor: 47.728

2.  Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000.

Authors:  James M Frincke; Dwight R Stickney; Nanette Onizuka-Handa; Armando Garsd; Christopher Reading; Srivicha Krudsood; Polrat Wilairatana; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2007-02       Impact factor: 2.345

3.  Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity.

Authors:  F P Siegal; C Lopez; P A Fitzgerald; K Shah; P Baron; I Z Leiderman; D Imperato; S Landesman
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors.

Authors:  S Feldman; D Stein; S Amrute; T Denny; Z Garcia; P Kloser; Y Sun; N Megjugorac; P Fitzgerald-Bocarsly
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

5.  Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients.

Authors:  V Soumelis; I Scott; F Gheyas; D Bouhour; G Cozon; L Cotte; L Huang; J A Levy; Y J Liu
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  16alpha-bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth.

Authors:  D Freilich; S Ferris; M Wallace; L Leach; A Kallen; J Frincke; C Ahlem; M Hacker; D Nelson; J Hebert
Journal:  Am J Trop Med Hyg       Date:  2000 Nov-Dec       Impact factor: 2.345

7.  16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis.

Authors:  Rogelio Hernández-Pando; Diana Aguilar-Leon; Hector Orozco; Alberto Serrano; Clarence Ahlem; Richard Trauger; Beatrix Schramm; Chris Reading; James Frincke; Graham A W Rook
Journal:  J Infect Dis       Date:  2004-12-09       Impact factor: 5.226

8.  16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity.

Authors:  Kodjo Ayi; Giuliana Giribaldi; Aleksei Skorokhod; Evelin Schwarzer; Patrick T Prendergast; Paolo Arese
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection.

Authors:  J Ferbas; J Navratil; A Logar; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

10.  16alpha-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression.

Authors:  Niels C Pedersen; Thomas W North; Richard Rigg; Chris Reading; Joanne Higgins; Christian Leutenegger; Gary L Henderson
Journal:  Vet Immunol Immunopathol       Date:  2003-08-15       Impact factor: 2.046
View more
  10 in total

1.  Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from Trypanosoma cruzi.

Authors:  Fabrício Fredo Naciuk; Jéssica do Nascimento Faria; Amanda Gonçalves Eufrásio; Artur Torres Cordeiro; Marjorie Bruder
Journal:  ACS Med Chem Lett       Date:  2020-04-27       Impact factor: 4.345

Review 2.  The immunology of tuberculosis: from bench to bedside.

Authors:  Keertan Dheda; Stephan K Schwander; Bingdong Zhu; Richard N van Zyl-Smit; Ying Zhang
Journal:  Respirology       Date:  2010-04       Impact factor: 6.424

Review 3.  The Immunoregulatory Actions of DHEA in Tuberculosis, A Tool for Therapeutic Intervention?

Authors:  Bettina Bongiovanni; Ariana Díaz; Natalia Santucci; Luciano David D'Attilio; Oscar Bottasso; Rogelio Hernández Pando; María Luisa Bay
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-06       Impact factor: 6.055

4.  16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs.

Authors:  F Nicoletti; D Conrad; A Wang; R Pieters; K Mangano; A van Heeckeren; S K White; J Frincke; C L Reading; D L Auci; D Stickney
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330

5.  Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive persons.

Authors:  Maria Florencia Quiroga; Matias Tomas Angerami; Natalia Santucci; Diego Ameri; Jose Luis Francos; Jorge Wallach; Omar Sued; Pedro Cahn; Horacio Salomón; Oscar Bottasso
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

6.  The use of anti-tuberculosis therapy for latent TB infection.

Authors:  Justin T Denholm; Emma S McBryde
Journal:  Infect Drug Resist       Date:  2010-07-21       Impact factor: 4.003

7.  16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment.

Authors:  Manuel Othoniel López-Torres; Brenda Marquina-Castillo; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Jorge A Barrios-Payan; Guillermina Baay-Guzman; Sara Huerta Yepez; Estela Bini; Ivan Torre-Villalvazo; Nimbe Torres; Armando Tovar; William Chamberlin; Yu Ge; Andrea Carranza; Rogelio Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2021-06-01       Impact factor: 5.732

Review 8.  Immunoendocrine interactions during HIV-TB coinfection: implications for the design of new adjuvant therapies.

Authors:  Guadalupe Veronica Suarez; Maria Belen Vecchione; Matias Tomas Angerami; Omar Sued; Andrea Claudia Bruttomesso; Oscar Adelmo Bottasso; Maria Florencia Quiroga
Journal:  Biomed Res Int       Date:  2015-05-14       Impact factor: 3.411

9.  A new parasiticidal compound in T. solium cysticercosis.

Authors:  Romel Hernández-Bello; Galileo Escobedo; Julio Cesar Carrero; Claudia Cervantes-Rebolledo; Charles Dowding; James Frincke; Chris Reading; Jorge Morales-Montor
Journal:  Biomed Res Int       Date:  2012-12-20       Impact factor: 3.411

10.  Molecular analysis of sarcoidosis lymph nodes for microorganisms: a case-control study with clinical correlates.

Authors:  Lary A Robinson; Prudence Smith; Dhruba J Sengupta; Jennifer L Prentice; Ramon L Sandin
Journal:  BMJ Open       Date:  2013-12-23       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.